依那西普联合甲氨蝶呤治疗类风湿性 关节炎的Meta分析

• 药品评价-循证医学研究 • 上一篇下一篇

依那西普联合甲氨蝶呤治疗类风湿性关节炎的Meta分析

肖敦明,孙园园,孙阿敏,余正

中国药科大学国际医药商学院,中国药科大学国际医药商学院,中国药科大学国际医药商学院,中国药科大学国际医药商学院

收稿日期:2016-12-18 修回日期:2017-02-08 出版日期:2017-02-25 发布日期:2017-01-25

A Meta-analysis of Etanercept Combined with Methotrexate in Treatment of Rheumatoid Arthritis

School of International Pharmaceutical Business of China Pharmaceutical University,School of International Pharmaceutical Business of China Pharmaceutical University,School of International Pharmaceutical Business of China Pharmaceutical University,

Received:2016-12-18 Revised:2017-02-08 Online:2017-02-25 Published:2017-01-25

摘要/Abstract

摘要： 目的：系统评价依那西普联合甲氨蝶呤治疗类风湿性关节炎(RA)的疗效和安全性。方法：计算机检索 Cochrane Library、PubMed、Sciencedirect、中国期刊全文数据库、中文科技期刊全文数据库和万方数据库，全面查找符合纳入标准的临床随机对照试验（randomized controlled trial，RCT），用RevMan 5.3 软件进行统计分析。结果：共纳入6个RCT，2个在国外，4个在国内，各试验间具有基线可比性。Meta分析结果显示：依那西普联合甲氨蝶呤治疗RA和甲氨蝶呤单独治疗RA在有效性指标（ACR20、ACR50、ACR70）和生化指标（C反应蛋白、血沉、类风湿因子）等方面的差异有统计学意义，而在不良反应、感染等方面的差异无统计学意义。结论：与甲氨蝶呤单独治疗RA相比，依那西普联合甲氨蝶呤治疗RA疗效高，安全性好，具有较好的临床适用性。

Abstract: Objective： To systematically evaluate the efficacy and safety of etanercept combined with methotrexate in the treatment of rheumatoid arthritis.Methods：Cochrane Library，PubMed，Sciencedirect，CNKI，VIP and Wanfang Database were searched. randomized controlled trials(RCTs) were included in this study.RevMan 5.3 software was used for statistical analysis.Results：6 RCTs were included in the study，2 in the foreign countries，4 in the country，the test has a baseline comparability.Meta-analysis showed that there were statistically significant differences in efficacy indices(ACR20，ACR50，ACR70)and biochemical parameters (C-reactive protein，erythrocyte sedimentation rate，rheumatoid factor)between etanercept and methotrexate and methotrexate significance，but in the adverse reactions，infection and other aspects of the difference was not statistically significant.Conclusion：Compared with methotrexate，etanercept combined with methotrexate has high curative effect，good safety and good clinical applicability.

肖敦明,孙园园,孙阿敏,余正. 依那西普联合甲氨蝶呤治疗类风湿性关节炎的Meta分析[J]. .

参考文献

[1] 佚名. 类风湿性关节炎的治疗指南[J]. 继续医学教育, 2005, 19(3):67-73.
[2] 李瑞, 孟庆刚. 类风湿性关节炎的临床治疗研究[J]. 中华中医药学刊, 2007, 25(7):1348-1352.
[3] 刘一, 刘恩溢, 黄琳,等. 鹿瓜多肽注射液治疗类风湿性关节炎疗效及安全性的Meta分析[J]. 中国药房, 2012(20):1890-1893.
[4] 中华医学会风湿病学分会. 类风湿关节炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(4):265-270.
[5] Felson D T, Anderson J J, Boers M, et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis[J]. Arthritis & Rheumatology, 1995, 38(6):727-35.
[6] Jadad A R, Moore R A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J]. Controlled Clinical Trials, 1996, 17(1):1-12.
[7] 王创明, 郑洵, 陈海波. 依那西普、甲氨蝶呤联合治疗对类风湿关节炎患者血清IL-1、COX-2、TNF-α的影响[J]. 北方药学, 2016, 13(4):117-118.
[8] Weinblatt M E, Kremer J M, Bankhurst A D, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate[J]. New England Journal of Medicine, 1999, 340(4): 253-259.
[9] Machado D A, Guzman R M, Xavier R M, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.[J]. Journal of Clinical Rheumatology Practical Reports on Rheumatic & Musculoskeletal Diseases, 2014, 20(1):25-33.
[10] 艾脉兴, 马丽, 赵孟君,等. 依那西普治疗活动性类风湿关节炎的安全性和有效性[J]. 中国新药杂志, 2007, 16(15):1208-1211.
[11] 赵艳红, 刘坚. 依那西普治疗活动性类风湿关节炎的临床疗效观察[J]. 海峡药学, 2012, 24(8):120-122.
[12] 姚巧巧, 黄钢红. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白靶向治疗类风湿关节炎的临床疗效观察[J]. 中国医药科学, 2011, 01(5):20-21.